A community oncology pharmacist explains how seeing patients across the course of their diagnosis builds trust and why accessibility remains the field’s biggest challenge despite advances in AI.
|Videos|August 9, 2017
How Specialty Pharmacists Can Prepare Patients to Switch to Biosimilars
Marcus H. Snow, MD, of the University of Nebraska Medical Center, discusses how education and counseling can improve the uptake of biosimilars among rheumatologists and patients.
Advertisement
Marcus H. Snow, MD, of the University of Nebraska Medical Center, discusses how education and counseling can improve the uptake of biosimilars among rheumatologists and patients.
Advertisement
Related to this article
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
2
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
3
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
4
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care
5